Poustchi et al conducted a population-based cross-sectional study on SARS-CoV-2 antibody seroprevalence across eighteen cities in Iran during the first wave of the epidemic (data collection ended on June 2); a total of 8,902 participants were included in the analysis (60% from high-risk occupations and 40% from the general public). The authors found the overall prevalence of antibody seropositivity was 17.1% in the general population and 20.0% in the high-risk population (with little variation among the occupations included). They also found a large variation in the seroprevalence of SARS-CoV-2-specific antibodies across cities. Individuals sixty and older had the highest age-stratified seroprevalence. The authors conclude that seroprevalence of SARS-CoV-2 in Iran is likely much higher than the prevalence of COVID-19 based on confirmed cases. Additionally, a large proportion of the population remains uninfected and susceptible to the virus.